Suppr超能文献

阿尔茨海默病的严重程度是否影响其对肠道微生物群调节的反应性?一项双盲临床试验。

Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial.

作者信息

Agahi Azadeh, Hamidi Gholam Ali, Daneshvar Reza, Hamdieh Mostafa, Soheili Masoud, Alinaghipour Azam, Esmaeili Taba Seyyed Mohammad, Salami Mahmoud

机构信息

Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.

Department of Neurology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

出版信息

Front Neurol. 2018 Aug 15;9:662. doi: 10.3389/fneur.2018.00662. eCollection 2018.

Abstract

Alzheimer's disease (AD) is associated with cognitive dysfunction. Evidence indicates that gut microbiota is altered in the AD and, hence, modifying the gut flora may affect the disease. In the previous clinical research we evaluated the effect of a probiotic combination on the cognitive abilities of AD patients. Since, in addition to pathological disorders, the AD is associated with changes in oxidant/antioxidant and inflammatory/anti-inflammatory biomarkers, the present work was designed to evaluate responsiveness of the inflammatory and oxidative biomarkers to the probiotic treatment. The control (CON) and probiotic (PRO) AD patients were treated for 12 weeks by the placebo and probiotic supplementation, respectively. The patients were cognitively assessed by Test Your Memory (TYM = 50 scores). Also serum concentrations of nitric oxide (NO), glutathione (GSH), total antioxidant capacity (TAC), malondialdehyde (MDA), 8-hydroxy-2' -deoxyguanosine (8-OHdG) and cytokines (TNF-a, IL-6, and IL-10) were measured. The cognitive test and the serum biomarkers were assessed pre- and post-treatment. According to TYM test 83.5% of the patients showed severe AD. The CON (12.86% ± 8.33) and PRO (-9.35% ± 16.83) groups not differently scored the cognitive test. Not pronounced change percent was found in the serum level of TNF-α (1.67% ± 1.33 vs. -0.15% ± 0.27), IL-6 (0.35% ± 0.17 vs. 2.18% ± 0.15), IL-10 (0.05% ± 0.10 vs. -0.70% ± 0.73), TAC (0.07% ± 0.07 and -0.06% ± 0.03), GSH (0.08% ± 0.05 and 0.04% ± 0.03) NO (0.11% ± 0.06 and 0.05% ± 0.09), MDA (-0.11% ± 0.03 and -0.17% ± 0.03), 8-OHdG (43.25% ± 3.01 and 42.70% ± 3.27) in the CON and PRO groups, respectively. We concluded that the cognitive and biochemical indications in the patients with severe AD are insensitive to the probiotic supplementation. Therefore, in addition to formulation and dosage of probiotic bacteria, severity of disease and time of administration deeply affects results of treatment.

摘要

阿尔茨海默病(AD)与认知功能障碍有关。有证据表明,AD患者的肠道微生物群发生了改变,因此,改变肠道菌群可能会影响该疾病。在之前的临床研究中,我们评估了一种益生菌组合对AD患者认知能力的影响。由于除了病理紊乱外,AD还与氧化/抗氧化和炎症/抗炎生物标志物的变化有关,因此本研究旨在评估炎症和氧化生物标志物对益生菌治疗的反应性。对照组(CON)和益生菌组(PRO)的AD患者分别接受了12周的安慰剂和益生菌补充治疗。通过“测试你的记忆力”(TYM = 50分)对患者进行认知评估。同时还测量了血清一氧化氮(NO)、谷胱甘肽(GSH)、总抗氧化能力(TAC)、丙二醛(MDA)、8-羟基-2'-脱氧鸟苷(8-OHdG)和细胞因子(TNF-α、IL-6和IL-10)的浓度。在治疗前和治疗后对认知测试和血清生物标志物进行评估。根据TYM测试,83.5%的患者患有重度AD。CON组(12.86%±8.33)和PRO组(-9.35%±16.83)在认知测试中的得分没有差异。CON组和PRO组血清中TNF-α(1.67%±1.33对-0.15%±0.27)、IL-6(0.35%±0.17对2.18%±0.15)、IL-10(0.05%±0.10对-0.70%±0.73)、TAC(0.07%±0.07和-0.06%±0.03)、GSH(0.08%±0.05和0.04%±0.03)、NO(0.11%±0.06和0.05%±0.09)、MDA(-0.11%±0.03和-0.17%±0.03)、8-OHdG(43.25%±3.01和42.70%±3.27)的水平变化均不明显。我们得出结论,重度AD患者的认知和生化指标对益生菌补充不敏感。因此,除了益生菌的配方和剂量外,疾病的严重程度和给药时间也会深刻影响治疗结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54e8/6104449/7bbdf3e0c9b9/fneur-09-00662-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验